An Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 11 Feb 2016
At a glance
- Drugs ENMD 2076 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Sponsors CASI Pharmaceuticals; EntreMed
- 07 Jan 2013 Status changed from active, no longer recruiting to completed, according to an EntreMed media release.
- 19 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 03 Aug 2011 Planned end date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.